8-K: P3 Health Partners Reports Q1 2026 Results, Raises Guidance

P3 Health Partners announced first quarter 2026 financial results, reporting $26 million in adjusted EBITDA and raising full-year adjusted EBITDA guidance to a midpoint of $40 million.

Summary

• P3 Health Partners reported first quarter 2026 financial results, marking a significant turning point with $26 million in adjusted EBITDA.
• The company is raising its full-year 2026 adjusted EBITDA outlook to a midpoint of $40 million, driven by strong Q1 performance and confidence in the business trajectory.
• Total revenue for Q1 2026 was $386 million, a 4% increase year-over-year, with per-member revenue up 14% due to contractual restructuring and rate progression.
• At-risk membership decreased by 10% to approximately 106,000 members, attributed to intentional network and payer rationalization.
• Net income for the quarter was $3.0 million, a substantial improvement from a net loss of $44.2 million in the prior year quarter.
• Medical margin for the quarter was $73.7 million, or $231 per member, though this includes favorable prior year development and payer settlements.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with the company showing a clear turnaround in profitability and raising future guidance, despite a decrease in membership.

Positives

• Achieved $26 million in adjusted EBITDA for Q1 2026, a significant improvement.
• Raised full-year 2026 adjusted EBITDA guidance to a midpoint of $40 million.
• Total revenue increased by 4% to $386 million in Q1 2026.
• Per-member revenue increased by 14% due to contractual restructuring and rate progression.
• Reported a net income of $3.0 million in Q1 2026, compared to a net loss of $44.2 million in Q1 2025.
• Medical margin was $73.7 million ($231 PMPM) in Q1 2026.

Negatives

• At-risk membership decreased by 10% to approximately 106,000 members in Q1 2026.
• The company has a substantial accumulated deficit of ($649.9 million) as of March 31, 2026.
• Total liabilities exceed total assets, resulting in a negative stockholders' deficit of ($143.5 million) as of March 31, 2026.
• Net cash used in operating activities was $27.5 million for the three months ended March 31, 2026.

Risks

• Potential need to raise additional capital to fund existing operations or expand services.
• Ability to achieve or maintain profitability.
• Maintaining compliance with debt covenants and potential need for waivers.
• Risk of non-cash charges for goodwill and intangible asset impairment if assumptions change.
• Ability to identify and develop successful new geographies, physician partners, payors, and patients.
• Changes in market conditions, regulatory environment, and competitive landscape.
• Maintaining relationships with health plans and other key payors.
• Impact of fluctuations in risk adjustments and increased labor and medical costs.

Future Outlook

The company is raising its full-year 2026 adjusted EBITDA outlook to a midpoint of $40 million, with a range of $20 million to $60 million. Full-year guidance also projects at-risk members between 103,000 and 110,000, total revenues between $1,500 million and $1,650 million, and medical margin between $190 million and $230 million.

Management Comments

• "Q1 represents a meaningful turning point for the business. The $26 million of adjusted EBITDA we delivered this quarter reflects the cumulative impact of two years of deliberate work, including contract restructuring, network concentration, and operational redesign."
• "Based on the strength of Q1 and our confidence in the underlying trajectory, we are raising our full-year 2026 adjusted EBITDA outlook to a midpoint of $40 million," said Dr. Aric Coffman, CEO of P3.

Industry Context

StockSavvy.ai notes that P3 Health Partners' results and guidance raise indicate a potential turnaround in the population health management sector, a segment focused on value-based care. The company's strategic rationalization of its network and payer contracts, while reducing membership, appears to be improving profitability metrics.

Comparison to Industry Standards

• The reported net income of $3.0 million for Q1 2026 contrasts with a significant net loss in the prior year, suggesting improved operational efficiency compared to many companies in the early stages of value-based care transition.
• The increase in per-member revenue by 14% is a positive indicator, outperforming industry averages that often struggle with revenue growth amidst cost pressures.
• The adjusted EBITDA of $81 PMPM is a key metric for this industry; while specific comparable figures for direct competitors are not provided in this filing, the positive trend is noteworthy.
• The company's focus on 'at-risk' membership, though declining, is a strategic shift towards higher-margin contracts, a trend seen across the value-based care landscape.

Stakeholder Impact

• Shareholders: Potential for improved stock performance due to positive financial results and raised guidance, though offset by ongoing financial challenges (accumulated deficit, negative equity).
• Employees: Improved financial health may lead to greater job security and potential for growth within the company.
• Providers: Continued focus on value-based care and physician-led management aims to support affiliated primary care providers.
• Payors: The company's strategy of network and payer rationalization may impact relationships, but improved performance could lead to stronger partnerships.

Next Steps

• Management to host a conference call and webcast on May 14, 2026, at 4:30 PM ET to discuss results.
• The company will continue to execute on its strategy of contract restructuring, network concentration, and operational redesign.

Key Dates

Recommendation

While the Q1 results and raised guidance are positive, indicating a significant turnaround and improved operational performance, the company still faces substantial financial challenges, including a large accumulated deficit and negative equity. The decrease in at-risk membership and the reliance on non-GAAP measures warrant caution. Therefore, a 'hold' recommendation is appropriate, pending further evidence of sustained profitability and balance sheet improvement.

Keywords

P3 Health Partners, 8-K, Q1 2026 Results, Adjusted EBITDA, Population Health Management, Healthcare, Financial Results, Guidance